会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • SELECTIVE GLUCOCORTICOID RECEPTOR AGONISTS
    • 选择性GLUCOCORTICOID受体激动剂
    • US20080090792A1
    • 2008-04-17
    • US11737185
    • 2007-04-19
    • Stephen BarrMichael McKerveyHughes MielDavid RayAndrew Brass
    • Stephen BarrMichael McKerveyHughes MielDavid RayAndrew Brass
    • A61K31/56A61K31/58A61P29/00A61P37/06A61P7/00
    • C07J5/0092C07J3/005C07J21/003C07J41/0011C07J41/0038
    • This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which comprises administering to a patient a compound that has the structure of Formula (I) or Formula (II) as defined below, or a pharmaceutically acceptable derivative thereof or pro-drug therefor, wherein R═NH2, NHR1, NHOR2, NHNHR2, NHCOR2, and R1═C(1-4)alkyl, C(3-6)cycloalkyl, Cn, where n=1-3, R2=methyl, ethyl, R3=alkyl, cycloalkyl, substituted alkyl, substituted cycloalkyl, aryl, heteroaryl, substituted aryl, or substituted hetrecoaryl; wherein R4, R5═C(1-4)alkyl. Novel compounds according to Formula (III), wherein R6 and R7 are any of H, CH3CO, CH3CH2CO, CH3CH2CH2CO provided that R6 and R7 are not both H, or Formula (IV), wherein R5 and R9 are any of H, CH3CO, CH3CH2CO or CH3CH2CH2CO, having use in such methods, are also described.
    • 本发明涉及治疗炎性病症,治疗血液学和其他恶性肿瘤,引起免疫抑制,或预防或治疗人或其他动物中的移植排斥的方法,其包括向患者施用具有式(I)结构的化合物, 或下式定义的式(II)或其药学上可接受的衍生物或其前体药物,其中R-NH 2,NHR 1,NHOR 2, ,NHNHR 2,NHCOR 2和R 1 -C 1-4烷基,(C 1 -C 4)烷基, C 3-6(C 3-6)环烷基,C n为N,其中n = 1-3,R 2 =甲基,乙基, 烷基,环烷基,取代的烷基,取代的环烷基,芳基,杂芳基,取代的芳基或取代的hetrecoaryl; 其中R 4,R 5 -C(1-4) - 烷基)。 根据式(III)的新型化合物,其中R 6和R 7是H,CH 3 CO,CH 3 CH 2 CO 2,CH 3 CH 2 CH 2 CO,条件是R 6 和/或R 7不同时为H或式(Ⅳ),其中R 5和R 9为H, CH 3 CO,CH 3 CH 2 CO或CH 3 CH 2 CH 2 也描述了在这些方法中使用的CO 2。
    • 6. 发明申请
    • Selective glucocorticoid receptor agonists
    • 选择性糖皮质激素受体激动剂
    • US20040102425A1
    • 2004-05-27
    • US10415711
    • 2003-12-05
    • Alexander Stephen BarrMichael Anthony McKerveyHughes Jean-Pierre MielDavid William RayAndrew Michael Brass
    • A61K031/58A61K031/573
    • C07J5/0092C07J3/005C07J21/003C07J41/0011C07J41/0038
    • This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which comprises administering to a patient a compound that has the structure of Formula (I) or Formula (II) as defined below, or a pharmaceutically acceptable derivative thereof or pro-drug therefor, wherein RnullNH2, NHR1, NHOR2, NHNHR2, NHCOR2, and R1nullC(1-4)alkyl, C(3-6)cycloalkyl, Cn, where nnull1-3, R2nullmethyl, ethyl, R3nullalkyl, cycloalkyl, substituted alkyl, substituted cycloalkyl, aryl, heteroaryl, substituted aryl, or substituted hetreoaryl; wherein R4, R5nullC(1-4)alkyl. Novel compounds according to Formula (III), wherein R6 and R7 are any of H, CH3CO, CH3CH2CO, CH3CH2CH2CO provided that R6 and R7 are not both H, or Formula (IV), wherein R8 and R9 are any of H, CH3CO, CH3CH2CO or CH3CH2CH2CO, having use in such methods, are also described.
    • 本发明涉及治疗炎性病症,治疗血液学和其他恶性肿瘤,引起免疫抑制,或预防或治疗人或其他动物中的移植排斥的方法,其包括向患者施用具有式(I)结构的化合物, 或下式定义的式(II)或其药学上可接受的衍生物或其前体药物,其中R = NH 2,NHR 1,NHOR 2,NHNHR 2,NHCOR 2和R 1 = C(1-4)烷基,C(3-6)环烷基,Cn,其中n = 1-3,R2 =甲基,乙基,R3 =烷基,环烷基,取代的烷基,取代的环烷基,芳基, 芳基或取代的杂芳基; 其中R 4,R 5 = C(1-4)烷基。 根据式(III)的新化合物,其中R 6和R 7是H,CH 3 CO,CH 3 CH 2 CO,CH 3 CH 2 CH 2 CO 2中的任何一个,条件是R 6和R 7不同时为H或式(IV) 其中R 8和R 9是在这些方法中使用的H,CH 3 CO,CH 3 CH 2 CO或CH 3 CH 2 CH 2 CO中的任何一种。